DePuy Orthopaedics Newswire

DePuy Orthopaedics Newswire

Comprehensive Real-Time News Feed for DePuy Orthopaedics.

Results 1 - 20 of 257 in DePuy Orthopaedics

  1. CureVac To Present At s 22nd Annual NewsMakers In The Biotech Industry ConferenceRead the original story

    Wednesday | BioSpace

    3, 2015 /PRNewswire/ -- CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that it will present at BioCentury's 22nd Annual NewsMakers in the Biotech Industry Conference to be held , Ph.D., co-founder and CEO of CureVac, will provide an overview of the company's business, industry-leading mRNA technology platform, and clinical-stage development pipeline during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. CureVac is the leading company in messenger RNA based drugs with more than 15 years of expertise and the most advanced and broadest clinical pipeline in the industry.

    Comment?

  2. Learning From Johnson & Johnson's Time In The $60sRead the original story w/Photo

    Tuesday Sep 1 | Seeking Alpha

    Johnson & Johnson is an excellent example of a company that continues to provide solid business performance year-in and year-out. Yet the stock price doesn't always reflect this: moving in fits and starts rather than in concert with the business results.

    Comment?

  3. 3 ways Tampa Bay can capitalize on the Johnson & Johnson dealRead the original story w/Photo

    Tuesday Sep 1 | Business Journal

    He said a strong workforce and great weather give Tampa Bay a competitive advantage over other areas in attracting shared service operations, or consolidation of business operations used by many parts of an organization, such as accounting, information technology, human resources and other support activities. The business case is purely driven by cost savings.

    Comment?

  4. Johnson & Johnson To Participate In The 2015 10th Annual Healthcare ConferenceRead the original story

    Thursday Aug 27 | BioSpace

    Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer, will represent the Company as the keynote speaker, and is scheduled to present at This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

    Comment?

  5. Bristol-Myers Squibb's success in Tampa was a major draw for Johnson & JohnsonRead the original story w/Photo

    Thursday Aug 27 | Business Journal

    There are a number of reasons Johnson & Johnson chose Tampa for its shared services North American headquarters, but Rick Homans believes there was one factor that really sealed the deal.

    Comment?

  6. Johnson & Johnson to Participate in the 2015 Wells Fargo 10th Annual Healthcare ConferenceRead the original story

    Thursday Aug 27 | DVDCreation Reviews

    Alex Gorsky, Chairman of the Board of Directors and Chief Executive Officer, will represent the Company as the keynote speaker, and is scheduled to present at This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

    Comment?

  7. J&J Makes a Sweet Deal to Sell SplendaRead the original story

    Wednesday Aug 26 | CFO

    In a move that may shake up the low-calorie sweetener market, Johnson & Johnson has agreed to sell its top-selling Splenda brand to Heartland Food Products Group. Heartland already makes sucralose, the sweetening agent in Splenda, as well as stevia, saccharin, aspartame, and other sweeteners.

    Comment?

  8. Johnson & Johnson (JNJ) Stock Up on Splenda SaleRead the original story w/Photo

    Tuesday Aug 25 | TheStreet.com

    Tate & Lyle had forecast for a 25% decrease in sucralose prices this year as sales are dragged by a decline in demand for carbonated soft drinks, Reuters added. Separately, TheStreet Ratings team rates JOHNSON & JOHNSON as a Buy with a ratings score of A-.

    Comment?

  9. Sears looks to boost Kenmore and Craftsman brands with new hireRead the original story

    Tuesday Aug 25 | WNFL-AM Green Bay

    Pendergrass will focus on boosting sales of the three brands while working with the appliances, lawn and garden, tools and auto center units. She will report to Chief Executive Officer Edward Lampert, a spokesman said.

    Comment?

  10. Johnson & Johnson exec to lead hardlines for SearsRead the original story w/Photo

    Monday Aug 24 | Retailing Today

    The company announced that Lynn Pendergrass has joined the company in the new role of president, hardlines. In this position, she will be responsible for working across the Kenmore, Craftsman & DieHard business unit and its hardlines partners - including Home Appliances, Lawn & Garden, Tools, and Sears Auto Centers - to develop compelling offers and build relationships with members who shop the hardline categories.

    Comment?

  11. Sears Holdings names J&J, HP exec as hardlines presidentRead the original story w/Photo

    Monday Aug 24 | Chain Store Age

    Lynn Pendergrass has joined Sears Holdings Corp. in the new role of president, hardlines. In this position, she will be responsible for working across the Kenmore, Craftsman & DieHard business unit and its hardlines partners, including home appliances, lawn & garden, tools, and Sears Auto Centers, to develop compelling offers and build customer relationships.

    Comment?

  12. Baby Wipe Industry 2019 Trends Forecasts for Global Markets (Procter...Read the original story w/Photo

    Monday Aug 24 | SBWire

    This is a professional and in-depth market survey on Global and Chinese Baby Wipe industry. The report firstly reviews the basic information of Baby Wipe including its classification, application and manufacturing technology.

    Comment?

  13. J&J Ceo Excused From Deposition in Qui Tam CaseRead the original story w/Photo

    Friday Aug 21 | Law.com

    Alex Gorsky, the former CEO of Novartis Pharmaceuticals and present head of Johnson & Johnson, does not have to give a deposition in a false-claims whistleblower case against Novartis, a federal judge has ruled.

    Comment?

  14. Janssen Pharmaceutical Ends Partnership With China's Hutchison MedipharmaRead the original story

    Tuesday Aug 18 | BioSpace

    Janssen Pharma, a Johnson & Johnson subsidiary, has ended its anti-inflammation collaboration with Hutchison MediPharma, the drug R&D arm of Hutchison China MediTech. HMP will continue to develop the collaboration's lead molecule, HMP-507, a small molecule candidate that targets a novel inflammation/immunology kinase.

    Comment?

  15. Edward a oeEda Blizzard Selected for Inclusion in The Best Lawyers in AmericaRead the original story

    Tuesday Aug 18 | Business Wire

    ... Joseph R. Goodwin. Appointed to the Plaintiff's Steering Committee, MDL Docket No. 1:10 md 2197, In Re: DePuy Orthopaedics, Inc. ASR Hip Implant Products ; in the United States District Court for the Northern District of Ohio, by the Hon. Judge ...

    Comment?

  16. Crowdsourcing your securityRead the original story w/Photo

    Tuesday Aug 18 | Network World

    The formal security programs at most companies include a finite number of managers and staffers. But the fact is, everyone within an organization should be responsible on some level for contributing to efforts to protect information, physical assets and other property.

    Comment?

  17. Reckitt given UK go-ahead for K-Y mergerRead the original story w/Photo

    Wednesday Aug 12 | Financial Times

    Competition authorities set out conditions for Reckitt Benckiser 's planned union of Durex condoms with K-Y lubricant in the UK on Wednesday, as they announced the findings of an investigation into the impact of the merger. Reckitt has been told that its planned purchase of K-Y from Johnson & Johnson can go ahead, but only if it in turn licenses the intimate lubricant brand in the UK to another group for eight years.

    Comment?

  18. Durex-maker Reckitt Benckiser cleared to purchase personal lubricant KY JellyRead the original story w/Photo

    Wednesday Aug 12 | Daily Mail

    Durex-maker Reckitt Benckiser has been cleared by competition authorities to buy personal lubricant, KY Jelly, but will have to licence the brand to a rival for eight years in the UK. The maker of Nurofen and Cillit Bang forked out A 260million to buy the brand from Johnson & Johnson but Britain's Competition and Markets Authority launched a probe in May. It was concerned that Durex and KY hold almost three-quarters of the market share in chemists and supermarkets in Britain and it could have blocked the deal.

    Comment?

  19. How Have Employment Levels Increased At Top Medtech Companies?Read the original story w/Photo

    Wednesday Aug 12 | Medical Device/Diagnostic Ind.

    Medtronic sits at the top of the medtech mountain in terms of employment, market cap and sales. But how have employment levels of other top companies changed since 2009? There are several headwinds making it tough going for medtech companies but largely because of mergers and acquisitions activity, employment levels at the largest device companies are on an upward trajectory.

    Comment?

  20. Reckitt forced to license K-Y brand as UK regulator approves dealRead the original story w/Photo

    Wednesday Aug 12 | Live Charts

    Reckitt Benckiser has been given clearance from the UK's competition regulator to buy the K-Y lubricants brand from Johnson & Johnson, but the consumer goods company will be forced to license out the brand to a UK competitor to alleviate concerns over competition. The Competition and Markets Authority said on Wednesday that Reckitt, which owns the Durex condom brand, will need to license the K-Y brand in the UK to a third party for eight years, during which time the other company will be given the chance to develop a new brand to compete with the Durex range.

    Comment?